Endo to Acquire Par Pharmaceutical, Strategically Expanding Generics Business to a Top 5 Industry Leader
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Piper Jaffray Raises Price Target on Endo Int'l (ENDP) Leading up to Par Pharma Acquisition
May 19, 2015 7:42 AM EDTPiper Jaffray reiterates an Overweight rating on Endo International plc (NASDAQ: ENDP), and raised the price target to $117.00 (from $110.00), leading up to the Par Pharmaceuticals acquisition. Endo plans on Acquiring Par for $8B.
Piper Jaffray analyst David Amsellem commented on Endo, saying, "Endo is... More
Endo Int'l (ENDP) Announces FDA Approval of Expanded XIAFLEX Label
May 18, 2015 6:34 AM EDTEndo Int'l (NASDAQ: ENDP) announced that the U.S. Food and Drug Administration (FDA) has approved a label update for XIAFLEX (collagenase clostridium histolyticum or CCH) for the treatment of adult Dupuytren's contracture (DC) patients with a palpable cord. The updated label now includes a long-term, observational study demonstrating the rate of recurrence for up to 5 years after successful treatment with XIAFLEX, and the efficacy and safety of retreatment in patients with recurrent DC.
DC is a chronic condition affecting the hand in which abnormal buildup of collagen can... More
